SCHEMBL2172852

SCHEMBL2172852

Fc1ccc2cc(CCl)cc(OCc3ccccc3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.41
MAPT P10636 4/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 4/20 0.40
ALOX5 P09917 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
STAT3 P40763 1/20 0.39
HTT P42858 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
PTGER1 P34995 1/20 0.38
LIPE Q05469 1/20 0.38
MRGPRX4 Q96LA9 2/20 0.38
KDM1A O60341 1/20 0.38
PPIA P62937 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172046 0.89 LIPE (0.41) L3MBTL1MAPTMAPK1TDP1LMNA
SCHEMBL6041334 0.84 MRGPRX4 (0.47) L3MBTL1MAPTMAPK1TDP1LMNA
SCHEMBL27841440 0.83 PTGDR2 (0.48) L3MBTL1MAPTLMNANPC1PTGER1
SCHEMBL27828553 0.82 L3MBTL1 (0.42) L3MBTL1MAPTMAPK1TDP1LMNA
SCHEMBL27822158 0.80 ALDH1A1 (0.52) L3MBTL1MAPTLMNANPC1PTGER1
SCHEMBL2175029 0.79 LMNA (0.43) L3MBTL1MAPTLMNANPC1PTGER1
SCHEMBL31667762 0.78 PTGER1 (0.56) PTGER1MRGPRX4MEN1KMT2A
SCHEMBL29230634 0.78 KMT2A (0.49) L3MBTL1MAPTTDP1LMNASMN1; SMN2
SCHEMBL2394736 0.78 L3MBTL1 (0.48) L3MBTL1MAPTMAPK1TDP1LMNA
SCHEMBL26731828 0.78 HTT (0.45) L3MBTL1MAPTMAPK1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2791111-B1 [4-(PIPERIDIN-4-YL)-NAPHTHALEN-2-YL]-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY DISORDERS HOFFMANN LA ROCHE (CH) 2017-01-18 EP disclosed
EP-2791111-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS F.HOFFMANN-LA ROCHE AG (CH) 2014-10-22 EP disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
US-8642629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2014-02-04 US disclosed
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
EP-2358677-B1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
WO-2013087544-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2013-06-20 WO disclosed
US-20130150407-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS HOFFMANN-LA ROCHE INC. (US) 2013-06-13 US disclosed
EP-2346819-B1 NAPHTHYLACETIC ACIDS HOFFMANN LA ROCHE (CH) 2013-04-10 EP disclosed
WO-2010055004-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
US-20100125061-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-05-20 US disclosed
WO-2010055004-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
WO-2010055006-A1 NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed
US-20100125058-A1 NAPHTHYLACETIC ACIDS CHEN LI 2010-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125058-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 L3MBTL1 4726/4885MAPT 4671/4885MAPK1 2528/4885
US-20100125061-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 L3MBTL1 4773/4885MAPT 4646/4885MAPK1 3005/4885
US-20130150407-A1 PIPERIDINYL NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 L3MBTL1 4845/4885MAPT 4620/4885MAPK1 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.